drugset / Trial / NCT07385248

A Clinical Trial to Assess the Pharmacokinetics and Safety of AD-229 Compared to AD-2291 in Healthy Adults

NCT07385248

Phase 1 Not yet recruiting 28 enrolled Addpharma Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

The study compare and evaluate the safety and pharmacokinetic characteristics between the administration of AD-229 and the administration of AD-2291 in healthy adults.

Timeline

Start
2026-04
Primary completion
2026-06
Completion
2026-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Rebamipide Small molecule 100 mg Oral
Subject Rebamipide Small molecule 300 mg Oral

Indications